Barclays analyst Etzer Darout raised the firm’s price target on Exelixis (EXEL) to $44 from $41 and keeps an Equal Weight rating on the shares as part of a Q4 earnings preview for the biotechnology group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential
- Exelixis reports zanzalintinib new drug application accepted for review by FDA
- Exelixis price target raised to $49 from $48 at Morgan Stanley
- Exelixis price target raised to $52 from $49 at H.C. Wainwright
- Exelixis price target raised to $51 from $49 at Truist